« Previous Case Study
Next Case Study »
Preparing the company for investor and partner discussions
Our client was a clinical stage company developing the next generation of oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company is progressing a strong pipeline of clinical and preclinical programs. In advance of communicating with investors and potential partners, the company asked for US market landscapes and revenue forecasts of the markets for six tumor types.
The NemetzGroup reviewed client documents and completed additional secondary research to inform forecast assumptions. The team also conducted primary research to capture KOL reaction to the product profiles and views on how the treatment landscape may evolve over the coming years.
US market landscape summaries and 15-year US, EU, and ROW revenue forecast models were developed for each of the tumor types.
Scheduling regular reviews with the program team and gaining alignment with the client on the forecast approach was critical to the success of this engagement. The client was able to use the forecast models to negotiate a term sheet with their partner. The NemetzGroup work was also leveraged in discussions with investors in advance of a public offering.